Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Deirdre Jill Cohen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6178-9266; OpenAlex author ID A5048973199; NIH RePORTER profile ID 10464813. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 1, last author 1)
Trials
2 (principal investigator on 2)
Grants
1
Labs led
0
Collaborators
67
Papers, trials and grants by year

2015: 4 papers · 2016: none · 2017: none · 2018: 3 papers, 1 trial · 2019: 1 paper, 1 grant · 2020: none · 2021: none · 2022: 1 paper · 2023: 3 papers, 1 trial · 2024: none · 2025: 3 papers

Papers 15

  1. Antibiotic treatment and survival in patients with resected, early-stage pancreatic ductal adenocarcinoma receiving chemotherapy. Co-author DOI 10.1093/jncics/pkaf024↗
  2. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study. Co-author DOI 10.1093/oncolo/oyaf271↗
  3. Examining the impact of specialty palliative care consultation in patients with metastatic pancreatic cancer: evaluating use at an NCI designated cancer center. Co-author DOI 10.21037/apm-24-121↗
  4. Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2023.4254↗
  5. Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer. Co-author DOI 10.1038/s41388-023-02606-9↗
  6. Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment. Last author DOI 10.1093/oncolo/oyad044↗
  7. BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer. Co-author DOI 10.1038/s41388-022-02425-4↗
  8. Harnessing the Microbiome for Pancreatic Cancer Immunotherapy. First author DOI 10.1016/j.trecan.2019.10.005↗
  9. RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2018.10.006↗
  10. The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Co-author DOI 10.1158/2159-8290.cd-17-1134↗
  11. Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation. Co-author DOI 10.21037/jgo.2017.10.04↗
  12. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… Co-author DOI 10.1093/annonc/mdv264↗
  13. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… Co-author DOI 10.1093/annonc/mdv477↗
  14. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Co-author DOI 10.1200/jco.2014.57.4244↗
  15. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1200/jco.2015.62.8719↗

Trials 2

  1. Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer Principal investigator NCT05462496↗
  2. Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer Principal investigator NCT03599362↗

Grants 1

  1. Regulation of Pancreatic Oncogenesis by RIP1 Kinase R01CA168611↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. George Miller · 5 shared papers, 1 shared grant, 2018–2023 · strength 0.91
  2. Sonal Gandhi · 2 shared papers, 2023–2025 · strength 0.49
  3. Fionnuala Crowley · 2 shared papers, 2023–2025 · strength 0.49
  4. Arielle J. Labiner · 2 shared papers, 2023–2025 · strength 0.47
  5. Keith Magnus Sigel · 2 shared papers, 2023–2025 · strength 0.47
  6. Daniel Jeremy Fulop · 2 shared papers, 2023–2025 · strength 0.47
  7. Aimee Lee Lucas · 2 shared papers, 2023–2025 · strength 0.47
  8. Berk Aykut · 4 shared papers, 2018–2023 · strength 0.34
  9. Elliot Newman · 2 shared papers, 2018–2025 · strength 0.31
  10. Gregor Werba · 3 shared papers, 2018–2023 · strength 0.29
  11. Brian E. Diskin · 3 shared papers, 2018–2023 · strength 0.29
  12. Aaron James Scott · 3 shared papers, 2015–2025 · strength 0.29
  13. Wells A. Messersmith · 3 shared papers, 2015–2025 · strength 0.29
  14. Wei Wang · 3 shared papers, 2018–2023 · strength 0.29
  15. Joshua Leinwand · 3 shared papers, 2018–2023 · strength 0.29
  16. Emma W. Gong · 1 shared paper, 2025 · strength 0.28
  17. Lawrence Leichman · 2 shared papers, 2015–2025 · strength 0.26
  18. Cardinale B. Smith · 1 shared paper, 2025 · strength 0.26
  19. Tanios Bekaii‐Saab · 1 shared paper, 2025 · strength 0.22
  20. Colin D. Weekes · 1 shared paper, 2025 · strength 0.22
  21. Alec J. Megibow · 1 shared paper, 2025 · strength 0.22
  22. Paul E. Oberstein · 1 shared paper, 2025 · strength 0.22
  23. Haley M. Zylberberg · 1 shared paper, 2023 · strength 0.18
  24. Gerardo A. Vitiello · 1 shared paper, 2019 · strength 0.16
  25. Emma Kurz · 2 shared papers, 2018 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.